EMBC - Embecta Corp.
New York, New York--(Newsfile Corp. - May 21, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Embecta Corp. ("Embecta Corp.") (NASDAQ: EMBC) concerning potential violations of the federal securities laws. On November 25, 2025, CFO Jacob P.
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Embecta Corp. (“Embecta” or the “Company”) (NASDAQ:EMBC) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On May 5, 2026, the Company reported second quarter 2026 earnings, which announced results below analyst expec.
Embecta's Q2 FY2026 revenue and EPS fell short of both company guidance and Wall Street consensus -- shares dropped more than 25% in a single session. NEW YORK, May 20, 2026 /PRNewswire/ -- Investors who held Embecta Corp. (NASDAQ: EMBC) shares lost more than 25% of their value when the stock collapsed after Q2 FY2026 earnings missed on both the top and bottom lines.
Embecta NASDAQ: EMBC President and CEO Devdatt Kurdikar said the company's recent U.S. business reset reflected a combination of customer-specific share loss, softer market trends and inventory-related factors, while emphasizing that the diabetes device maker is continuing a broader diversification strategy intended to make the business less dependent on its core insulin injection franchise.
PARSIPPANY, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global leader in diabetes care technology, today announced that it has completed its previously announced transaction to acquire Owen Mumford Holdings Limited (“Owen Mumford”), a privately held, UK-based innovator and manufacturer of medical devices and drug delivery technologies.
NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (NASDAQ: EMBC) stock dropped more than 25% after the company reported Q2 FY2026 earnings release, which reported results below analyst expectations and included a reduction to full-year 2026 guidance. Shareholders who lost money on their Embecta investment are encouraged to submit their information here.
Embecta Corp. (EMBC) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Embecta guided investors toward a $1.071-$1.093 billion revenue outlook for FY2026 while internal indicators reportedly already signaled the need for a cut -- shares later fell more than 25%. NEW YORK, May 13, 2026 /PRNewswire/ -- Shareholders who purchased Embecta Corp. (NASDAQ: EMBC) stock lost more than 25% of their investment value after the company slashed its full-year FY2026 financial outlook, reversing guidance it had publicly reaffirmed just months earlier.
PARSIPPANY, N.J., May 08, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC) today announced that management will present at the 2026 BofA Securities Global Health Care Conference in Las Vegas on Wednesday, May 13, 2026 at 3:00 p.m.
New York, New York--(Newsfile Corp. - May 7, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Embecta Corp. ("Embecta Corp.") (NASDAQ: EMBC) concerning potential violations of the federal securities laws. On November 25, 2025, CFO Jacob P.
Embecta faces accelerating revenue declines, with Q2 2026 sales down 14% and U.S. revenues plunging 29%. EMBC's high debt load could become unsustainable if the revenue declines continue. The company slashed its dividend from $0.15 to $0.01 per quarter. There is a buyback program, but I'm not sure it will be fully executed.
SAN DIEGO, May 06, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Embecta Corp. (NASDAQ: EMBC). The investigation focuses on Embecta's executive officers and whether investor losses may be recovered under federal securities laws.
Embecta's recent quarterly report arrived with disappointing results. Sales and earnings for fiscal Q2 came in far weaker than anticipated.
Embecta Corp. (EMBC) Q2 2026 Earnings Call Transcript
PARSIPPANY, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.01 for each issued and outstanding share of the Company's common stock. The dividend is payable on June 15, 2026 to stockholders of record at the close of business on May 28, 2026. About embecta
PARSIPPANY, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today reported second quarter fiscal 2026 financial results.
PARSIPPANY, N. J. , May 05, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. ("embecta") (Nasdaq: EMBC) has declared a quarterly cash dividend of $0. 01 for each issued and outstanding share of the Company's common stock.
PARSIPPANY, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, will host a conference call to discuss its fiscal second quarter 2026 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m.
The S&P 600 Small Cap index offers exposure to quality small-cap stocks with earnings requirements, providing growth potential and less analyst coverage. Eight S&P 600 small-cap dividend stocks meet the 'IDEAL' criteria: dividends from $1K invested exceed share price and free cash flow supports payouts. Top ten S&P 600 small-cap dividend dogs are projected to deliver an average 64.97% net gain by April 2027, with above-market volatility.
EMBC to acquire Owen Mumford for up to $199.4M, aiming to expand beyond diabetes into high-value drug delivery and boost long-term growth.